0001437749-23-014859.txt : 20230516
0001437749-23-014859.hdr.sgml : 20230516
20230516214725
ACCESSION NUMBER: 0001437749-23-014859
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230331
FILED AS OF DATE: 20230516
DATE AS OF CHANGE: 20230516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Berard Todd
CENTRAL INDEX KEY: 0001633186
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36362
FILM NUMBER: 23929523
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER NAME:
FORMER CONFORMED NAME: Beard Todd
DATE OF NAME CHANGE: 20150209
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC
CENTRAL INDEX KEY: 0000834365
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 943076866
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4254011400
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: BIOLIFE SOLUTION INC
DATE OF NAME CHANGE: 20030113
FORMER COMPANY:
FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4/A
1
rdgdoc.xml
FORM 4/A
X0407
4/A
2023-03-31
2023-04-10
0000834365
BIOLIFE SOLUTIONS INC
BLFS
0001633186
Berard Todd
C/O BIOLIFE SOLUTIONS, INC.
3303 MONTE VILLA PARKWAY, SUITE 310
BOTHELL
WA
98021
1
Chief Marketing Officer
1
Common Stock
2023-03-31
4
M
0
3610
A
121422
D
Common Stock
2023-04-06
4
S
0
1545
20.03
D
119877
D
Restricted Stock Award
0
2023-03-31
4
M
0
3610
0
D
Common Stock
3610
0
D
The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 3,610 shares.
/s/ Todd C.J. Berard
2023-05-16